Cargando…

IgA vasculitis (Henoch–Schönlein purpura): refractory and relapsing disease course in the adult population

BACKGROUND: The disease course of adult immunoglobulin A (IgA) vasculitis (IgAV; Henoch–Schönlein purpura) has not been well defined. METHODS: In a retrospective survey, we studied 85 adult IgAV patients with extended follow-up (median 43 months) for 67 patients. RESULTS: Only 33 of 67 (49%) achieve...

Descripción completa

Detalles Bibliográficos
Autores principales: Van de Perre, Els, Jones, Rachel B, Jayne, David R W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323141/
https://www.ncbi.nlm.nih.gov/pubmed/34345419
http://dx.doi.org/10.1093/ckj/sfaa251
_version_ 1783731186816778240
author Van de Perre, Els
Jones, Rachel B
Jayne, David R W
author_facet Van de Perre, Els
Jones, Rachel B
Jayne, David R W
author_sort Van de Perre, Els
collection PubMed
description BACKGROUND: The disease course of adult immunoglobulin A (IgA) vasculitis (IgAV; Henoch–Schönlein purpura) has not been well defined. METHODS: In a retrospective survey, we studied 85 adult IgAV patients with extended follow-up (median 43 months) for 67 patients. RESULTS: Only 33 of 67 (49%) achieved complete remission. Ongoing renal disease was the most common persistent organ manifestation, but extra-renal disease activity was also present in >50% of patients not achieving complete remission. Twenty-nine of 67 (43%) had relapsing disease, with 18/67 (27%) experiencing several relapses. Skin disease was the most common feature in relapsing patients, followed by nephritis. At 4 years of follow-up, 6 of 29 (21%) experienced progressive disease and 10/29 (34%) relapsing disease. Five of 67 (7%) developed nephritis after diagnosis, within the first 6 months of follow-up. At final follow-up, 10 of 67 (15%) had chronic kidney disease Stage ≥G3a, 18 (27%) haematuria and 13 (19%) proteinuria. No therapy appeared particularly effective and only 6/17 patients treated with mycophenolate mofetil experienced a good response. CONCLUSIONS: The disease course of adult IgAV is different from that seen in children, with higher frequency of persisting and relapsing disease. Renal disease is the main determinant of ongoing disease activity, but extra-renal features were seen in >50% of patients with chronic disease activity. No clear conclusions on use or choice of immunosuppressive agent could be made based on our experience.
format Online
Article
Text
id pubmed-8323141
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83231412021-08-02 IgA vasculitis (Henoch–Schönlein purpura): refractory and relapsing disease course in the adult population Van de Perre, Els Jones, Rachel B Jayne, David R W Clin Kidney J Original Articles BACKGROUND: The disease course of adult immunoglobulin A (IgA) vasculitis (IgAV; Henoch–Schönlein purpura) has not been well defined. METHODS: In a retrospective survey, we studied 85 adult IgAV patients with extended follow-up (median 43 months) for 67 patients. RESULTS: Only 33 of 67 (49%) achieved complete remission. Ongoing renal disease was the most common persistent organ manifestation, but extra-renal disease activity was also present in >50% of patients not achieving complete remission. Twenty-nine of 67 (43%) had relapsing disease, with 18/67 (27%) experiencing several relapses. Skin disease was the most common feature in relapsing patients, followed by nephritis. At 4 years of follow-up, 6 of 29 (21%) experienced progressive disease and 10/29 (34%) relapsing disease. Five of 67 (7%) developed nephritis after diagnosis, within the first 6 months of follow-up. At final follow-up, 10 of 67 (15%) had chronic kidney disease Stage ≥G3a, 18 (27%) haematuria and 13 (19%) proteinuria. No therapy appeared particularly effective and only 6/17 patients treated with mycophenolate mofetil experienced a good response. CONCLUSIONS: The disease course of adult IgAV is different from that seen in children, with higher frequency of persisting and relapsing disease. Renal disease is the main determinant of ongoing disease activity, but extra-renal features were seen in >50% of patients with chronic disease activity. No clear conclusions on use or choice of immunosuppressive agent could be made based on our experience. Oxford University Press 2021-01-11 /pmc/articles/PMC8323141/ /pubmed/34345419 http://dx.doi.org/10.1093/ckj/sfaa251 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Van de Perre, Els
Jones, Rachel B
Jayne, David R W
IgA vasculitis (Henoch–Schönlein purpura): refractory and relapsing disease course in the adult population
title IgA vasculitis (Henoch–Schönlein purpura): refractory and relapsing disease course in the adult population
title_full IgA vasculitis (Henoch–Schönlein purpura): refractory and relapsing disease course in the adult population
title_fullStr IgA vasculitis (Henoch–Schönlein purpura): refractory and relapsing disease course in the adult population
title_full_unstemmed IgA vasculitis (Henoch–Schönlein purpura): refractory and relapsing disease course in the adult population
title_short IgA vasculitis (Henoch–Schönlein purpura): refractory and relapsing disease course in the adult population
title_sort iga vasculitis (henoch–schönlein purpura): refractory and relapsing disease course in the adult population
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323141/
https://www.ncbi.nlm.nih.gov/pubmed/34345419
http://dx.doi.org/10.1093/ckj/sfaa251
work_keys_str_mv AT vandeperreels igavasculitishenochschonleinpurpurarefractoryandrelapsingdiseasecourseintheadultpopulation
AT jonesrachelb igavasculitishenochschonleinpurpurarefractoryandrelapsingdiseasecourseintheadultpopulation
AT jaynedavidrw igavasculitishenochschonleinpurpurarefractoryandrelapsingdiseasecourseintheadultpopulation